搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Staphylococcus aureus Phosphate import ATP-binding protein PstB (pstB) CSB-YP643870SKZ
CSB-EP643870SKZ
CSB-BP643870SKZ
CSB-MP643870SKZ
CSB-EP643870SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Indole-3-glycerol phosphate synthase (trpC) CSB-YP643871SKZ
CSB-EP643871SKZ
CSB-BP643871SKZ
CSB-MP643871SKZ
CSB-EP643871SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Nuclease sbcCD subunit D (sbcD) CSB-YP643872SKZ
CSB-EP643872SKZ
CSB-BP643872SKZ
CSB-MP643872SKZ
CSB-EP643872SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Aerobic glycerol-3-phosphate dehydrogenase (glpD), partial CSB-YP643873SKZ
CSB-EP643873SKZ
CSB-BP643873SKZ
CSB-MP643873SKZ
CSB-EP643873SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Ribosome maturation factor RimP (rimP) CSB-YP643874SKZ
CSB-EP643874SKZ
CSB-BP643874SKZ
CSB-MP643874SKZ
CSB-EP643874SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus ATP-dependent protease subunit HslV (hslV) CSB-YP643875SKZ
CSB-EP643875SKZ
CSB-BP643875SKZ
CSB-MP643875SKZ
CSB-EP643875SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Ribosome maturation factor RimM (rimM) CSB-YP643876SKZ
CSB-EP643876SKZ
CSB-BP643876SKZ
CSB-MP643876SKZ
CSB-EP643876SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Methionyl-tRNA formyltransferase (fmt) CSB-YP643877SKZ
CSB-EP643877SKZ
CSB-BP643877SKZ
CSB-MP643877SKZ
CSB-EP643877SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Isoleucine--tRNA ligase (ileS), partial CSB-YP643878SKZ
CSB-EP643878SKZ
CSB-BP643878SKZ
CSB-MP643878SKZ
CSB-EP643878SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Carbamate kinase 1 (arcC1) CSB-YP643879SKZ
CSB-EP643879SKZ
CSB-BP643879SKZ
CSB-MP643879SKZ
CSB-EP643879SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Phenylalanine--tRNA ligase alpha subunit (pheS) CSB-YP643880SKZ
CSB-EP643880SKZ
CSB-BP643880SKZ
CSB-MP643880SKZ
CSB-EP643880SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Phosphopantetheine adenylyltransferase (coaD) CSB-YP643881SKZ
CSB-EP643881SKZ
CSB-BP643881SKZ
CSB-MP643881SKZ
CSB-EP643881SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Ribonuclease J 1 (SAUSA300_0989), partial CSB-YP643882SKZ
CSB-EP643882SKZ
CSB-BP643882SKZ
CSB-MP643882SKZ
CSB-EP643882SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Probable quinol oxidase subunit 4 (qoxD), partial CSB-YP643883SKZ1
CSB-EP643883SKZ1
CSB-BP643883SKZ1
CSB-MP643883SKZ1
CSB-EP643883SKZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Probable glycolipid permease ltaA (ltaA), partial CSB-YP643884SKZ
CSB-EP643884SKZ
CSB-BP643884SKZ
CSB-MP643884SKZ
CSB-EP643884SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Coenzyme A disulfide reductase (cdr) CSB-YP643885SKZ
CSB-EP643885SKZ
CSB-BP643885SKZ
CSB-MP643885SKZ
CSB-EP643885SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Putative peptidyl-prolyl cis-trans isomerase (SAUSA300_0857) CSB-YP643886SKZ
CSB-EP643886SKZ
CSB-BP643886SKZ
CSB-MP643886SKZ
CSB-EP643886SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Na (+)/H (+) antiporter subunit G1 (mnhG1), partial CSB-YP643887SKZ1
CSB-EP643887SKZ1
CSB-BP643887SKZ1
CSB-MP643887SKZ1
CSB-EP643887SKZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Probable nitronate monooxygenase (SAUSA300_0825) CSB-YP643888SKZ
CSB-EP643888SKZ
CSB-BP643888SKZ
CSB-MP643888SKZ
CSB-EP643888SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Enolase (eno) CSB-YP643889SKZ
CSB-EP643889SKZ
CSB-BP643889SKZ
CSB-MP643889SKZ
CSB-EP643889SKZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>